Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
In the United States, Europe and many other countries, Herceptin is approved in combination with chemotherapy for the adjuvant (post-surgery) treatment of HER2-positive early breast cancer, first-line treatment of advanced HER2-positive breast cancer and first-line treatment of advanced HER2-positive gastric cancer. In Europe and other countries, it is also approved in combination with chemotherapy for the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer.
▼ If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at [email protected]